image

We cordially invite you to our seminar. 

“Investing in Biotech in Europe from Seed to Exit: Latest Trends”

During the seminar we will handle topics such as:

  • Pitfalls when launching a biotech venture out of university, in-licensing IP and know-how from the tech transfer office, suitable deal terms with institutional VC investors, managing the conflict of interest of the spin-off as a university scientist and shareholder of the venture business.
  • Accelerated exit by an structured M&A deal with big pharma – taking advantage of crossover financing – managing multiple tracks to secure funding – seamless work streams towards IPO or trade sale.

Please register early to ensure your slot.

If you wish to attend the seminar, please send the reply card until 27 April.

Registration via email.

Investing in Biotech in Europe from Seed to Exit: Latest Trends

Date & Time

3 May 2018 | 1:30 pm - 6:00 pm

Location

Baker McKenzie Munich
Theatinerstrasse 23
80333 Munich
Germany

Speakers

Guest Speakers

  • Dr. Michael Brandkamp
    Managing Director
      High-Tech Gründerfonds
  • Dr. J. Donald (Don) deBethizy
    Chairman
      Albumedix Ltd
  • Dr. Franz-Werner Haas, LLD, LL.M.
    Member of the Board/CCO
      CureVac AG
  • Prof. Dr. med. Gunter Hartmann
    Director
      Institute of Clinical Chemistry and Clinical
  • Dr. Ulrich Kinzel
    Managing Director
      goetzpartners securities Ltd
  • Dr. Karin Kleinhans
    Associate
      LSP – Life Sciences Partners
  • Dr. Matthias Kromayer
    Member of the Board/General Partner
      MIG AG
  • Dr. Holger N. Reithinger
    General Partner
      Forbion
  • Dr. Joachim (JR) Rothe
    General Partner
      LSP – Life Sciences Partners
  • Dr. Christian Stein
    Managing Director
      Ascenion GmbH
  • Prof. Dr. med. Dr. Thomas Thum
    Founder
      Cardior Pharmaceuticals GmbH
  • Dr. Claudia Ulbrich
    Managing Partner
      ulbrich & partner management consulting